
CLAIMS

1. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a human subject, wherein :

   a) an initial dose of the pharmaceutical composition comprising 100 to 600 mg of a compound of Formula (II)is to be administered within from onset of fever to 72 hours after fever onset due to dengue infection; and

   b) a plurality of subsequent doses of the pharmaceutical composition, wherein each of said plurality of subsequent doses comprises 25 to 300 mg of a compound of Formula (II), are to be administered three to four times per day until there is an improvement in the infection or between from 1 day to 10 days, Formula (II) having the following structure,



(II),

or a pharmaceutically acceptable salt thereof.

2. The use of Claim 1, wherein the dengue viral infection comprises at least one dengue virus selected from DENV1, DENV2, DENV3 and DENV4.

3. The use of Claim 1 or 2, wherein the dengue viral infection is secondary dengue infection.

4. The use of any one of Claims 1-3, wherein the human subject to be treated is positive prior to treatment for a dengue infection using a NS1 strip assay or quantitative PCR.

5. The use of any one of Claims 1-4, wherein an initial dose comprising 150 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 100 mg of the compound are to be administered to the human subject three to four times per day for 1-5 days.

6. The use of any one of Claims 1-4, wherein an initial dose comprising 150 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to the human subject four times per day for 1-5 days.

7. The use of any one of Claims 1-4, wherein an initial dose comprising 150 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to the human subject three times per day for 1-5 days.

8. The use of any one of Claims 1-4, wherein an initial dose comprising 150 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 200 mg of the compound are to be administered to the human subject three to four times per day for 1-5 days.

9. The use of any one of Claims 1-4, wherein an initial dose comprising 200 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 100 mg of the compound are to be administered to the human subject three to four times per day for 1-5 days.

10. The use of any one of Claims 1-4, wherein an initial dose comprising 200 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to the human subject three to four times per day for 1-5 days.


11. The use of any one of Claims 1-4, wherein an initial dose comprising 200 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 200 mg of the compound are to be administered to the human subject three to four times per day for 1-5 days.

12. The use of any one of Claims 1-4, wherein a divided initial dose comprising 100 to 600 mg of the compound is to be administered to the human subject and thereafter, subsequent doses comprising 25 to 300 mg of the compound are to be administered to the human subject three to four times per day for between 5 days to 10 days.

13. Use of a compound of Formula (II) in the preparation of a pharmaceutical composition for treating a dengue virus (DENV) infection in a plurality of human subjects, wherein:

a) an initial dose of the pharmaceutical composition comprising 100 to 600 mg of a compound of Formula (II) is to be administered to each of the plurality of human subjects within from onset of fever to 72 hours after fever onset due to dengue infection; and

b) a plurality of subsequent doses of the pharmaceutical composition, wherein each of said plurality of subsequent doses comprises 25 to 300 mg of a compound of Formula (II), are to be administered three to four times per day to each of the plurality of human subjects until there is an improvement in the infection or between from 1 day to 10 days, Formula (II) having the following structure,



(II),

or a pharmaceutically acceptable salt thereof.

14. The use of Claim 13, wherein dengue viral infection comprises at least one dengue virus selected from DENV1, DENV2, DENV3 and DENV4.

15. The use of Claim 13 or 14, wherein the dengue viral infection is secondary dengue infection.

16. The use of any one of Claims 13-15, wherein each of the plurality of human subjects to be treated is positive prior to treatment for a dengue infection using a NS1 strip assay or quantitative PCR.

17. The use of any one of Claims 13-16, wherein an initial dose comprising 150 mg of the compound is to be administered to each of the plurality of human subjects and thereafter, subsequent doses comprising 100 mg of the compound are to be administered to each of the plurality of human subjects three to four times per day for 1-5 days.

18. The use of any one of Claims 13-16, wherein an initial dose comprising 150 mg of the compound is to be administered to each of the plurality of human subjects and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to each of the plurality of human subjects four times per day for 1-5 days.

19. The use of any one of Claims 13-16, wherein an initial dose comprising 150 mg of the compound is to be administered to each of the plurality of human subjects and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to each of the plurality of human subjects three times per day for 1-5 days.

20. The use of any one of Claims 13-16, wherein an initial dose comprising 150 mg of the compound is to be administered to each of the plurality of human subjects and thereafter, subsequent doses comprising 200 mg of the compound are to be administered to each of the plurality of human subjects three to four times per day for 1-5 days.

21. The use of any one of Claims 13-16, wherein an initial dose comprising 200 mg of the compound and thereafter, subsequent doses comprising 100 mg of the compound are to be administered to each of the plurality of human subjects three to four times per day for 1-5 days.

22. The use of any one of Claims 13-16, wherein an initial dose comprising 200 mg of the compound is to be administered to each of the plurality of human subjects and thereafter, subsequent doses comprising 150 mg of the compound are to be administered to each of the plurality of human subjects three to four times per day for 1-5 days.

23. The use of any one of Claims 13-16, wherein an initial dose comprising 200 mg of the compound is to be administered to each of the plurality of human subjectsand thereafter, subsequent doses comprising 200 mg of the compound are to be administered to each of the plurality of human subjects three to four times per day for 1-days.

24. The use of any one of Claims 13-16, wherein a divided initial dose comprising 100 to 600 mg of the compound is to be administered to each of the plurality of human subjects and thereafter, subsequent doses comprising 25 to 300 mg of the compound are to be administered to each of the plurality of human subjects three to four times per day for between 5 days to 10 days.